Mean change of SBP/DBP (S-AM Vs Amlo) Standing: −24.21/−13.08 vs −21.6/−13.44 Supine: −27.13/−14.17 vs −22.04/−13.68 Sitting: −26.86/−14.17 vs −23.06/−14.28
Mean change of SBP/DBP (S-AM Vs Amlo) Standing: −22.6/−12.72 vs −21.96/−13.24 Supine: −22.84/−13.18 vs −22.32/−13.4 Sitting: −20.16/−13.76 vs −22.24/−15.0
Mean change of SBP/DBP (S-AM Vs Amlo) Standing: −19.22/−13.63 vs −19.14/−12.76 Supine: −19.69/−13.95 vs −19.24/−13.33 Sitting: −19.87/−14.31 vs −19.24/−13.05
LSM reduction SBP: −15.9 vs −12.7 DBP: −7.3 vs −5.3 HR: −3 vs −4
Number: 8 vs 16
Hu and Xiao (2013) [56] [S-AM + Irbesartan vs Indapamide + Irbesartan]
China
NA
Indapamide
83
12–24
At 12 and 24 weeks Lower 24-h DBPV, day-time SBPV with S-AM than Indapamide At 24 weeks Significantly lower morning SBP, 24-h DBPV and SBPV
NA
Ihm et al. (2016) [28] [Telmisartan + S-AM FDC (CKD-828): 2.5/40 and 2.5/80]
Korea
2.5
S-AM 2.5
63/63/61
8
Mean NP change in groups: 2.5/40 & 5/40 vs S-AM 2.5 SBP: −12.89, −13.79 vs −4.55 DBP: −9.67, −10.72 vs −4.93 Differences in mean change: SBP: −4.34 () and −5.61 () DBP: −4.73 () and −5.79 () Achieving BP <140 or <90 mmHg: 60.32% (), 60.66% () vs 28.33%
9.52% (), 14.29% () vs 27.87%
Park et al. (2016) [29] [Telmisartan + S-AM FDC: 2.5/40 and 2.5/80 mg]
Korea
2.5 & 5
T (80)
61/60/62
8
2.5/40 & 5/40 Vs T80 SBP: −10.56, −12.32 vs −2.44 DBP: −8.12, −9.58 vs −1.76 ( for both) Achieving target BP <140 or <90: 35.59%, 40.68% vs 11.86%